Last Updated: November 16, 2026

MYHIBBIN Drug Patent Profile

« Back to Dashboard


Which patents cover Myhibbin, and what generic alternatives are available?

Myhibbin is a drug marketed by Azurity and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in MYHIBBIN is mycophenolate mofetil. There is one drug master file entry for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the mycophenolate mofetil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Myhibbin

A generic version of MYHIBBIN was approved as mycophenolate mofetil by SANDOZ on October 15th, 2008.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for MYHIBBIN?
  • What are the global sales for MYHIBBIN?
  • What is Average Wholesale Price for MYHIBBIN?
Summary for MYHIBBIN
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Patent Applications: 2,543
What excipients (inactive ingredients) are in MYHIBBIN?MYHIBBIN excipients list
DailyMed Link:MYHIBBIN at DailyMed
Pharmacology for MYHIBBIN

US Patents and Regulatory Information for MYHIBBIN

MYHIBBIN is protected by five US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Azurity MYHIBBIN mycophenolate mofetil SUSPENSION;ORAL 216482-001 May 1, 2024 RX Yes Yes 12,194,143 ⤷  Start Trial Y ⤷  Start Trial
Azurity MYHIBBIN mycophenolate mofetil SUSPENSION;ORAL 216482-001 May 1, 2024 RX Yes Yes 11,931,455 ⤷  Start Trial Y ⤷  Start Trial
Azurity MYHIBBIN mycophenolate mofetil SUSPENSION;ORAL 216482-001 May 1, 2024 RX Yes Yes 12,097,285 ⤷  Start Trial Y ⤷  Start Trial
Azurity MYHIBBIN mycophenolate mofetil SUSPENSION;ORAL 216482-001 May 1, 2024 RX Yes Yes 12,226,526 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for MYHIBBIN

See the table below for patents covering MYHIBBIN around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3836898 SUSPENSION PHARMACEUTIQUE POUR FORME GALÉNIQUE ORALE (PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE) ⤷  Start Trial
United Kingdom 202103764 ⤷  Start Trial
United Kingdom 2591396 Pharmaceutical suspension for oral dosage ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2020039263 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for MYHIBBIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0281713 SPC/GB96/026 United Kingdom ⤷  Start Trial PRODUCT NAME: MYCOPHENOLATE MOFETIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 53337 19951103; CH 53338 19951103; UK EU/1/96/005/001 19960214; UK EU/96/005/002 19960214
0281713 96C0031 Belgium ⤷  Start Trial PRODUCT NAME: MYCOPHENOLATE MOFETIL; NAT. REGISTRATION NO/DATE: EU/1/96/005/001 19960214; FIRST REGISTRATION: CH 53337 19951103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.